Cisplatin and peripheral arterial thromboembolic events

dinsdag 24 november 2015 9:00

Cisplatin (generic, Platosin®), member of the platinum-containing anti-cancer drugs, is indicated for the treatment of several types of extensive or metastatic tumors like testicular carcinoma, ovarian carcinoma and lung carcinoma. Cancer patients are known to have an increased risk of venous and arterial thromboembolic events (VTEs/ATEs). Venous thromboembolism is already a known adverse drug reaction of cisplatin. Thereby mention Dutch SmPCs for cisplatin arterial events like myocardial infarction, cerebrovascular accident and occlusion of the common carotid artery as well.